AIR BioSolutions
Reducing Immunoassay Costs and Advancing Methodological Efficiency
AIR BioSolutions (Advanced Immunoassay Research Ltd.) is an emerging spinoff dedicated to producing cost savings for life sciences research. Founded by CPPFD member Dr. Anthony Ness, the company focuses on the development of consumable research products for protein-based experiments. Research products are tested to match or exceed comparative gold standard methods and products. AIR BioSolutions develops autofluorescence quenchers and blocking solutions for immunofluorescence and immunoassays.
Enhancing Resource Optimization and Sustainability in Laboratory Workflows
Novel technologies include specialized reagents and validated protocols designed to enable reliable, sequential reuse of enzyme-linked immunosorbent assays (ELISAs) and western blots. Standard immunoassay methodologies routinely demand a high consumption of specialized reagents and consumables. AIR addresses these operational constraints by introducing refined stripping and preparation technologies that preserve assay sensitivity and matrix integrity across multiple testing cycles, without compromising quantitative accuracy.
-
Resource Optimization: Significantly reduces the standard expenditure on high-cost primary antibodies and specialized detection reagents.
-
Environmental Sustainability: Minimizes laboratory plastic, chemical, and biological waste footprints by extending the functional lifecycle of assay platforms.
-
Data Maximization: Facilitates iterative protocol applications to extract comprehensive datasets from limited or high-value biological samples.
AIR's official website will be launching soon.
